FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Troy Sarich

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Phenomena

Partial Thromboplastin Time

Anatomy

Thrombosis

Co-author Network

Publications

TOP 3
Troy C Sarich; Dorota B Schranz; Margery A Connelly; Keith T Demarest; Atalanta Ghosh; Elizabeth T Leary; Prasarn Manitpisitkul; Paul Rothenberg; Bruce Damiano
Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans.
Margery A Connelly; Tom J Parry; Edward C Giardino; Zhihong Huang; Wai-Man Cheung; Cailin Chen; Frank Cools; Henk Van der Linde; David J Gallacher; Gee-Hong Kuo; Troy C Sarich; Keith T Demarest; Bruce P Damiano
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
Hassan Dorani; Kajs-Marie Schützer; Troy C Sarich; Ulrika Wall; Ulrika Logren; Lis Ohlsson; Ulf G Eriksson
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Troy Sarich (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Troy C Sarich; Dorota B Schranz; Margery A Connelly; Keith T Demarest; Atalanta Ghosh; Elizabeth T Leary; Prasarn Manitpisitkul; Paul Rothenberg; Bruce Damiano
Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans.
International journal of clinical pharmacology and therapeutics 2012;50(8):584-94.
2010: Margery A Connelly; Tom J Parry; Edward C Giardino; Zhihong Huang; Wai-Man Cheung; Cailin Chen; Frank Cools; Henk Van der Linde; David J Gallacher; Gee-Hong Kuo; Troy C Sarich; Keith T Demarest; Bruce P Damiano
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
Journal of cardiovascular pharmacology 2010;55(5):459-68.
2007: Hassan Dorani; Kajs-Marie Schützer; Troy C Sarich; Ulrika Wall; Ulrika Logren; Lis Ohlsson; Ulf G Eriksson
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
European journal of clinical pharmacology 2007;63(6):571-81.
2007: Andras Gruber; Stefan Carlsson; Harry F Kotzé; Ulla M Marzec; Troy C Sarich; Stephen R Hanson
Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
Thrombosis research 2007;119(1):121-7.
2006: Ulf G Eriksson; Hassan Dorani; Johan Karlsson; Holger Fritsch; Kurt-Jürgen Hoffmann; Lis Olsson; Troy C Sarich; Ulrika Wall; Kajs-Marie Schützer
Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(5):775-82.
2006: Karin Wåhlander; Maria Eriksson-Lepkowska; Per Nyström; Ulf G Eriksson; Troy C Sarich; Juan J Badimon; Inge Kalies; Margareta Elg; Anders Bylock
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Thrombosis and haemostasis 2006;95(3):447-53.
2005: Christer Mattsson; Troy C Sarich; Stefan C Carlsson
Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
Seminars in vascular medicine 2005;5(3):235-44.
2005: Stefan C Carlsson; Christer Mattsson; Ulf G Eriksson; Troy C Sarich; Karin Wåhlander; Asa Eliasson; Björn W Karlson; Sunita B Sheth; Peter Held
A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.
Thrombosis research 2005;115(1-2):9-18.
2004: Renli Teng; Troy C Sarich; Ulf G Eriksson; Jennifer E Hamer; Stephen Gillette; Kajs-Marie Schützer; Glenn F Carlson; Peter R Kowey
A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
Journal of clinical pharmacology 2004;44(9):1063-71.
2004: Troy C Sarich; Kajs-Marie Schützer; Maria Wollbratt; Ulrika Wall; Eva Kessler; Ulf G Eriksson
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
Journal of clinical pharmacology 2004;44(8):935-41.
2004: Troy C Sarich; Kajs-Marie Schützer; Hassan Dorani; Ulrika Wall; Inge Kalies; Lis Ohlsson; Ulf G Eriksson
No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
Journal of clinical pharmacology 2004;44(8):928-34.
2004: Michael Wolzt; Marcel Levi; Troy C Sarich; Stig L Boström; Ulf G Eriksson; Maria Eriksson-Lepkowska; Mia Svensson; Jeffrey I Weitz; Margareta Elg; Karin Wåhlander
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Thrombosis and haemostasis 2004;91(6):1090-6.
2004: Troy C Sarich; Susanne Johansson; Kajs-Marie Schützer; Ulrika Wall; Eva Kessler; Renli Teng; Ulf G Eriksson
The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
Journal of clinical pharmacology 2004;44(4):388-93.
2004: Kajs-Marie Schützer; Ulrika Wall; Carina Lönnerstedt; Lis Ohlsson; Renli Teng; Troy C Sarich; Ulf G Eriksson
Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation.
Current medical research and opinion 2004;20(3):325-31.
2004: Stig L Boström; Göran F H Hansson; Troy C Sarich; Michael Wolzt
The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Thrombosis research 2004;113(1):85-91.
2003: Stig L Boström; Göran F H Hansson; Magnus Kjaer; Troy C Sarich
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2003;14(5):457-62.
2003: Troy C Sarich; Julio Osende; Ulf G Eriksson; Gunnar Fager; Maria Eriksson-Lepkowska; Lis Ohlsson; Stefan Carlsson; Karin Wåhlander; David Gustafsson; J J Badimon
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
Journal of thrombosis and haemostasis : JTH 2003;1(5):999-1004.
2003: Michael Wolzt; Stig L Boström; Mia Svensson; Karin Wåhlander; Margaretha Grind; Troy C Sarich
Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.
Pathophysiology of haemostasis and thrombosis 2003;33(2):68-74.
2003: Troy C Sarich; Michael Wolzt; Ulf G Eriksson; Christer Mattsson; Alice Schmidt; Susanne Elg; Magnus Andersson; Maria Wollbratt; Gunnar Fager; David Gustafsson
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Journal of the American College of Cardiology 2003;41(4):557-64.
2003: Troy C Sarich; Renli Teng; Gary R Peters; Maria Wollbratt; Robert Homolka; Mia Svensson; Ulf G Eriksson
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Clinical pharmacokinetics 2003;42(5):485-92.
2002: Troy C Sarich; Ulf G Eriksson; Christer Mattsson; Michael Wolzt; Lars Frison; Gunnar Fager; David Gustafsson
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Thrombosis and haemostasis 2002;87(2):300-5.